Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer [0.03%]
免疫检查点抑制剂在前列腺癌中的精准治疗及联合策略
Nicolas Sayegh,Zeynep Irem Ozay,Tian Zhang et al.
Nicolas Sayegh et al.
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study [0.03%]
一项关于转移性去势抵抗性前列腺癌的多中心、两队列、Ⅱ期NEPTUNES研究：具有免疫原性特征患者的Nivolumab和Ipilimumab治疗
Gianmarco Leone,Yien Ning Sophia Wong,Robert J Jones et al.
Gianmarco Leone et al.
Purpose: Efficacy of immune checkpoint inhibitors in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is limited. The NEPTUNES study evaluated combination nivolumab and ipilimumab in patien...
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial [0.03%]
改良的5-氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂或S-1、伊立替康和奥沙利铂与白蛋白结合型紫杉醇+吉西他滨治疗转移性或复发性胰腺癌：一项随机、开放标签、II/III期临床试验（GENERATE，JCOG1611）
Akihiro Ohba,Masato Ozaka,Junki Mizusawa et al.
Akihiro Ohba et al.
Purpose: Modified FOLFIRINOX (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancreatic cancer. S-1, irinotecan, and oxaliplatin (S-IROX) demonstrated activity in a p...
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas [0.03%]
针对DLK+小细胞肺癌或神经内分泌癌患者I期剂量递增研究：DLL3/CD3 IgG样T细胞衔接物Obrixtamig（BI 764532）的结果
Martin Wermke,Valentina Gambardella,Yasutoshi Kuboki et al.
Martin Wermke et al.
Purpose: We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), extrapulmonary neur...
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 [0.03%]
BO-112联合派姆单抗治疗PD-1抗体耐药的晚期黑色素瘤患者的Ⅱ期临床试验：Spotlight-203研究 纠误通知书
Iván Márquez-Rodas,Caroline Dutriaux,Philippe Saiag et al.
Iván Márquez-Rodas et al.
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology [0.03%]
证据的总体性：优化肿瘤学中的剂量选择策略
Laura A Levit,Mirat Shah,Mark J Ratain et al.
Laura A Levit et al.
Derek De-Rui Huang,James Chih-Hsin Yang
Derek De-Rui Huang
Jacqueline Nguyen,Devika Das,Chintan V Shah
Jacqueline Nguyen